LeadStory

CNBC

Novartis raises outlook on strong second-quarter sales

CNBC · New
CNBC
CNBC
New

CNBC's Karen Gilchrist weighs in on Novartis' second-quarter earnings and efforts to diversify its drug portfolio beyond its blockbuster Entresto heart failure treatment.

Breakdown
  • Novartis raised its operating income outlook after strong second-quarter results.
  • Net sales rose 11% and operating income increased by 21%. 10s
  • A $10 billion share buyback was announced, reflecting confidence in future growth. 24s
  • Novartis is diversifying its portfolio beyond Entresto, highlighting drugs for breast cancer, multiple sclerosis, and cholesterol. 40s
  • The company faces challenges from upcoming US patent expiry for Entresto and potential US tariffs, but has not yet commented on the tariffs. 1m 3s
HealthBusiness